Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
- First Posted Date
- 2004-07-20
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9369
- Registration Number
- NCT00088010
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elk Grove, Illinois, United States
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1713
- Registration Number
- NCT00087711
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sutton, United Kingdom
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 77
- Registration Number
- NCT00087698
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
Effects of Arzoxifene on Bone Mass and the Uterus
- Conditions
- Postmenopausal Bone Loss
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2007-03-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00085956
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
- Conditions
- MetastasesNeoplasmColorectal Neoplasms
- Interventions
- Biological: cetuximab
- First Posted Date
- 2004-06-02
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 87
- Registration Number
- NCT00083720
- Locations
- 🇨🇦
ImClone Investigational Site, Toronto, Ontario, Canada
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
- Conditions
- Endometrial Cancer
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00003669
- Locations
- 🇺🇸
Huntington Memorial Hospital, Pasadena, California, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerPrimary Peritoneal Cavity Cancer
- First Posted Date
- 2004-05-21
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00003670
- Locations
- 🇺🇸
Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States
🇺🇸Abington Memorial Hospital, Abington, Pennsylvania, United States
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
- Conditions
- Ovarian Cancer
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT00082212
- Locations
- 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00079872
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sevilla, Spain
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2007-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT00079924
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States